Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (US20130131030) Optimizing mifepristone absorption

Office : United States of America
Application Number: 13677465 Application Date: 15.11.2012
Publication Number: 20130131030 Publication Date: 23.05.2013
Grant Number: 10500216 Grant Date: 10.12.2019
Publication Kind : B2
IPC:
A61K 31/575
A61K 31/567
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
56
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
575
substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
56
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
565
not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
567
substituted in position 17 alpha, e.g. mestranol, norethandrolone
CPC:
A61K 31/567
A61K 31/575
Applicants: CORCEPT THERAPEUTICS, INC.
Inventors: Joe Belanoff
Robert Roe
Caroline Loewy
Agents: Kilpatrick Townsend & Stockton LLP
Priority Data:
Title: (EN) Optimizing mifepristone absorption
Abstract:
(EN)

The present invention provides a method for altering the pharmacokinetics of mifepristone upon oral administration. Mifepristone absorption into the blood is increased upon administration with meals. The method of the invention can benefit patients suffering from conditions including psychiatric illnesses and hormonal disorders.